Implementation of a large liquid biopsy genomic profiling assay in a decentralised setting

Implementation of a large liquid biopsy genomic profiling assay in a decentralised setting

Large panel (300+ genes) liquid biopsy assays hold the promise of delivering comprehensive genomic insights from a simple blood draw, but many laboratories hesitate to bring this in house due to perceived cost, technical and operational challenges.

Recent advances are rapidly changing this landscape. Improvements in library preparation workflows, decreasing cost per sample—even at smaller batch sizes—and compatibility with mid-throughput sequencing instruments are making liquid biopsy CGP research more accessible than ever. Compared to FFPE tissue, plasma workflows can also offer shorter turnaround times and streamlined laboratory processes, enabling laboratories to deliver genomic insights when tissue is limited, unavailable, or results are needed quickly.

In this webinar, Dr. Gang Zheng MD, PhD, will share experience from the Mayo Clinic laboratory, how the lab approaches liquid biopsy and recent implementation data of a liquid biopsy assay to enable comprehensive genomic profiling (CGP).

Attendees will learn:

• An introduction to liquid biopsy
• What liquid biopsy options Mayo Clinic offers and why
• Why Mayo Clinic decided to bring a large panel liquid biopsy research assay in house
• Performance of TSO 500 ctDNA v2 across key variant classes (SNVs, Indels, CNVs, Rearrangements, large gene signatures) and inputs such as blood and cerebral spinal fluid (CSF)
• Analytical accuracy and reproducibility supporting deployment
• Approaches to CHIP detection and filtering to ensure confident variant reporting
• Concordance to solid tumor CGP FFPE tissue assay
• Comparative performance insights versus a liquid biopsy send-out assay

For Research Use Only. Not for use in diagnostic procedures.

Speakers:

Dr. Gang Zheng, MD, PhD Co-director Mayo Clinic Genomics Laboratory, Professor of the Department of Laboratory Medicine & Pathology Mayo Clinic Dr. Gang Zheng is board certified in both molecular pathology and hematopathology. He is a co-director of Mayo Clinical genomics laboratory and a professor of the department of laboratory medicine and pathology. Dr. Zheng currently served as the chair for the molecular diagnostic committee of international society of laboratory hematology, an expert advisor for molecular diagnostics and a co-chair for document development committee on liquid biopsy methods for oncology at CLSI (Clinical & Laboratory Standards Institute). He is on editorial boards of multiple journals and has been invited as a speaker to national and international conferences. Dr. Zheng's clinical and research interests include implementing cutting edge molecular technologies including liquid biopsy in oncology, and integration of genomic, morphologic and clinical data to facilitate better clinical decision-making with genomic data. Member, editorial board, Journal of Applied Laboratory Medicine, 2019-present Expert adviser for molecular diagnostics, Clinical and Laboratory Standards Institute, 2020 Review editor, Hematologic Malignancies, Frontiers in Oncology, 2020 Review editor, Hematologic Malignancies, Frontiers in Oncology, 2020 Vice chair, Molecular Analysis committee, International Society for Laboratory Hematology, 2020